Drug Trial Radar · NCT02055781
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Nov 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
311
Actual
Start
Feb 2014
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- CTI BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
Conditions
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
PacritinibDrug
Best Available TherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen Volume ReductionTime frame: Baseline to Week 24
- Total Symptom Score (TSS) ReductionTime frame: Baseline to Week 24
Locations
122 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona
Arizona Clinical Research Center
Tucson, Arizona
City of Hope
Duarte, California
Moores Cancer Centre
La Jolla, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Stanford Cancer Center
Stanford, California
Rocky Mountain Cancer Center
Boulder, Colorado
George Washington University- Medical Faculty Associates
Washington D.C., District of Columbia
SCRI- Florida Cancer Specialists South Region
Fort Myers, Florida
SCRI - Florida Cancer Specialists North Region
St. Petersburg, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Northwestern University
Chicago, Illinois
Carle Cancer Center
Urbana, Illinois
Indiana University Goshen Cancer Centre
Goshen, Indiana
Investigative Clinical Research of Indiana
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Siouxland Hematology-Oncology Associates, L.L.P (SHOA)
Sioux City, Iowa
Norton Cancer Institute, Suburban
Louisville, Kentucky
St Joseph Mercy Hospital
Ann Arbor, Michigan
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Providence Cancer Institute
Southfield, Michigan
Washington University School of Medicine Division of Oncology
St Louis, Missouri
Nebraska Hematology-Oncology, P.C.
Lincoln, Nebraska
Hackensack University
Hackensack, New Jersey
Hematology-Oncology Associates of Northern Jersey
Morristown, New Jersey
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
Mount Sinai Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
SCRI-Oncology Hematology Care
Cincinnati, Ohio
Cleveland Clinic-Taussig Cancer Center
Cleveland, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Upstate Oncology Associates
Greenville, South Carolina
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee
Texas Onocolgy-Baylor Sammons Cancer Center
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
UTMB Galveston
Galveston, Texas
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.